6 assets in MHC Class II Deficiency

Therapeutic assets addressing MHC Class II Deficiency, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alemtuzumab MHC Class II Deficiency	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Busulfanum MHC Class II Deficiency	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Cyclophosphamide MHC Class II Deficiency	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Fludarabine MHC Class II Deficiency	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Melphalan MHC Class II Deficiency	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Mesna MHC Class II Deficiency	Masonic Cancer Center, University of Minnesota	N/A	D (30)